Search
Search Results
##search.searchResults.foundPlural##
-
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
1948PDF: 574Suppl. Files: 270HTML: 150 -
THE EFFECT OF ALPHA THALASSEMIA, HBF and HBC ON HAEMATOLOGICAL PARAMETERS OF SICKLE CELL DISEASE PATIENTS IN IBADAN, NIGERIA. ALPHA THALASSEMIA, HBF and HBC ON HAEMATOLOGICAL PARAMETERS OF SICKLE CELL DISEASE PATIENTS
2160PDF: 923HTML: 56 -
PREVALENCE OF ALPHA THALASSEMIA IN MICROCYTIC ANEMIA: A TERTIARY CARE EXPERIENCE FROM NORTH INDIA
2295PDF: 1195HTML: 4644table: 187fig 1: 184fig 2: 154 -
STUDY OF SERUM HAPTOGLOBIN LEVEL AND ITS RELATION TO ERYTHROPOIETIC ACTIVITY IN BETA THALASSEMIA CHILDREN .
2091PDF: 1131HTML: 2572Study of serum haptoglobin level in thalassemia: 317Figures: 158 -
APLASTIC ANEMIA AND VIRAL HEPATITIS
1215PDF: 514HTML: 22992 -
-
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
2757PDF: 1536HTML: 216 -
HEMATOPOIETIC STEM CELL TRNSPLANTATION IN THALASSEMIA AND RELATED DISORDERS
1351PDF: 476HTML: 3941 -
THALASSEMIA AND VENOUS THROMBOEMBOLISM
2865PDF: 980HTML: 4561 -
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3306PDF: 1263HTML: 1846Fig.1: 182Fig. 2: 188 -
Anemia in the elderly: not always what it seems.
3233PDF: 987HTML: 1752Figure 1: 157Figure 1 revised: 162 -
CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
4128PDF: 1486HTML: 426 -
-
Measurement of erythrocyte lifespan using a CO breath test in patients with thalassemia and the impact of treatment erythrocyte lifespan in patients with thalassemia
679PDF: 505HTML: 128 -
A SEROPREVALENCE OF HBV, HCV AND HIV-1 AND CORRELATION WITH MOLECULAR MARKERS AMONG MULTI-TRANSFUSED THALASSEMIA PATIENTS IN WESTERN INDIA Incidence of serology & molecular of HIV, HBV and HCV in thalassemia patients
1258PDF: 740HTML: 466 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2250PDF: 1542HTML: 579 -
VASCULAR ENDOTHELIAL GROWTH FACTOR IN CHILDREN WITH THALASSEMIA MAJOR PDF
1239PDF: 830HTML: 1023Figure 1 the correlation between frequency of blood transfusion and serum vascular endothelial growth factor (VEGF).: 155 -
VITAMIN D STATUS IN THALASSEMIA MAJOR: AN UPDATE
2560PDF: 1043HTML: 2533 -
-
-
MODULATING EFFECT OF THE ?158 G? (C?T) XMN-1 POLYMORPHISM IN INDIAN SICKLE CELL PATIENTS
1442PDF: 861HTML: 1401Table: 175 -
GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS
2668PDF: 972HTML: 397TABLE: 170FIGURES: 211 -
SICKLE CELL DISEASE AND VENOUS THROMBOEMBOLISM
2174PDF: 829HTML: 2062 -
IS HEMOGLOBIN E GENE WIDELY SPREAD IN THE STATE OF MADHYA PRADESH IN CENTRAL INDIA? EVIDENCE FROM FIVE TYPICAL FAMILIES
1305PDF: 835HTML: 7908Untitled: 186 -
NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF SICKLE CELL DISEASE Guest Editor: Raffaella Origa
6672PDF: 3551HTML: 723 -
THE ROLE OF THE CAROTID DOPPLER EXAMINATION IN THE EVALUATION OF ATHEROSCLEROTIC CHANGES IN BETA THALASSEMIA PATIENTS
2082PDF: 877HTML: 2987Untitled: 180







